AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...
Azafaros will host a satellite symposium entitled "The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience" on February 3 at 17:45 PT, ...
Front Cover -- Designing Science Presentations -- Designing Science Presentations -- Copyright -- Contents -- About the author -- Acknowledgments -- 1 -- Using design ...
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead ...
Five presentations will showcase nizubaglustat's therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results